AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34134645 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation therapy (Control)
Number of subjects: 1032
Study 32009464 — intervention group
Group type: EXPERIMENTAL
Intervention: Email/mail outreach in Phase 1
Number of subjects: 185150
Study 32009464 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure outreach in Phase 2
Number of subjects: 185150
Study 32009464 — intervention group
Group type: COMPARATOR
Intervention: Overall recruitment in Phase 1
Number of subjects: 185150
Study 32009464 — intervention group
Group type: COMPARATOR
Intervention: Overall recruitment in Phase 2
Number of subjects: 185150
Study 36140688 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype F18
Number of subjects: 21
Study 36140688 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype F49
Number of subjects: 21
Study 36140688 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes P13 and P5
Number of subjects: 21
Study 36140688 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall genotypes
Number of subjects: 21
Study 36140688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis
Number of subjects: 21
Study 36140688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis
Number of subjects: 21
Study 36140688 — intervention group
Group type: EXPERIMENTAL
Intervention: PC analysis
Number of subjects: 21
Study 33354803 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvac® (two doses, 28 days apart)
Number of subjects: 19
Study 33354803 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatments
Number of subjects: 19
Study 35016426 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention
Number of subjects: 140
Study 35016426 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing intervention
Number of subjects: 140
Study 32026836 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise training (WG)
Number of subjects: 50
Study 32026836 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise training (LG)
Number of subjects: 50
Study 35058251 — intervention group
Group type: EXPERIMENTAL
Intervention: Total flavonoid intake (highest quintile)
Number of subjects: 55413
Study 35058251 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid subclasses (highest intake)
Number of subjects: 55413
Study 35058251 — intervention group
Group type: EXPERIMENTAL
Intervention: Total flavonoid intake (current smokers)
Number of subjects: 55413
Study 35058251 — intervention group
Group type: EXPERIMENTAL
Intervention: Total flavonoid intake (former smokers)
Number of subjects: 55413
Study 35058251 — intervention group
Group type: COMPARATOR
Intervention: Flavonoid intake
Number of subjects: 55413
Study 33998067 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβ-CD Ang-(1–7)
Number of subjects: 60
Study 33998067 — intervention group
Group type: COMPARATOR
Intervention: HPβ-CD
Number of subjects: 60
Study 33434503 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-normal LNs (defined as cN0 on CT scanning, PET scanning, and CLNS evaluation)
Number of subjects: 57
Study 34318743 — intervention group
Group type: COMPARATOR
Intervention: Peripherally inserted central catheters (n=212)
Number of subjects: 1061
Study 34318743 — intervention group
Group type: COMPARATOR
Intervention: PORTs (n=253)
Number of subjects: 1061
Study 34318743 — intervention group
Group type: COMPARATOR
Intervention: PORTs (n=147)
Number of subjects: 1061
Study 32744184 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive maternal observation of fetal movements
Number of subjects: 623
Study 32744184 — intervention group
Group type: COMPARATOR
Intervention: Routine-care (Control)
Number of subjects: 623
Study 36368992 — intervention group
Group type: EXPERIMENTAL
Intervention: Android-based self-care application
Number of subjects: 60
Study 36368992 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 60
Study 33756524 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% MVC static exercise
Number of subjects: 45
Study 33756524 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% MVC static exercise
Number of subjects: 45
Study 33756524 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% MVC dynamic exercise
Number of subjects: 45
Study 33756524 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% MVC dynamic exercise
Number of subjects: 45
Study 34400199 — intervention group
Group type: EXPERIMENTAL
Intervention: REP + LPRF
Number of subjects: 23
Study 34400199 — intervention group
Group type: COMPARATOR
Intervention: REP - LPRF
Number of subjects: 23
Study 32456572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp Oil Extract (60 mg/d, 15 mg hemp-derived CBD)
Number of subjects: 65
Study 32456572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 65
Study 33620619 — intervention group
Group type: EXPERIMENTAL
Intervention: Active esophageal cooling using the Attune Medical Esophageal Heat Transfer Device (EnsoETM)
Number of subjects: 44
Study 33620619 — intervention group
Group type: COMPARATOR
Intervention: Standard temperature monitoring (control group)
Number of subjects: 44
Study 33620619 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive posterior wall isolation
Number of subjects: 44
Study 33620619 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 44
Study 33866000 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 803
Study 37306270 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure extubation (PPE) with pressure support of 15 cm H2O and positive end expiratory pressure of 10 cm H2O for 5 minutes
Number of subjects: 70
Study 37306270 — intervention group
Group type: COMPARATOR
Intervention: Traditional extubation (TE)
Number of subjects: 70
Study 34836429 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPIFED (integrates cognitive behavioural therapy with body weight loss therapy)
Number of subjects: 98
Study 34836429 — intervention group
Group type: COMPARATOR
Intervention: CBT‐E (cognitive behavioural therapy with extended sessions alone)
Number of subjects: 98
Study 34836429 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPIFED
Number of subjects: 98
Study 32558044 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 48
Study 32558044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33356033 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors in addition to baseline treatment (Group A)
Number of subjects: 97
Study 33356033 — intervention group
Group type: COMPARATOR
Intervention: Baseline treatment or other medications as needed (Group B)
Number of subjects: 97
Study 33356033 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (Group C)
Number of subjects: 97
Study 34746955 — intervention group
Group type: COMPARATOR
Intervention: ExComb (HIIT and MICT combined)
Number of subjects: 1567
Study 34746955 — intervention group
Group type: COMPARATOR
Intervention: HIIT (high-intensity interval training)
Number of subjects: 1567
Study 34746955 — intervention group
Group type: COMPARATOR
Intervention: MICT (moderate-intensity continuous training)
Number of subjects: 1567
Study 34746955 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (instructed to follow physical activity recommendations)
Number of subjects: 1567
Study 34746955 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1567
Study 33325066 — intervention group
Group type: EXPERIMENTAL
Intervention: Family nursing therapeutic conversations
Number of subjects: 468
Study 33325066 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 468
Study 36429537 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (CG)
Number of subjects: 30
Study 32807060 — intervention group
Group type: EXPERIMENTAL
Intervention: High uric acid tertile
Number of subjects: 671
Study 32807060 — intervention group
Group type: EXPERIMENTAL
Intervention: High uric acid group
Number of subjects: 671
Study 32807060 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium uric acid group
Number of subjects: 671
Study 32807060 — intervention group
Group type: COMPARATOR
Intervention: Uric acid tertiles
Number of subjects: 671
Study 35429485 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily risdiplam
Number of subjects: 0
Study 35429485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34348723 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A - Package of interventions aimed at health service delivery optimization
Number of subjects: 39
Study 34348723 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B - Strengthening community platforms in addition to Arm A
Number of subjects: 39
Study 34348723 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 39
Study 35600575 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 68
Study 35600575 — intervention group
Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 68
Study 35600575 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin plus Exenatide
Number of subjects: 68
Study 35600575 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 68
Study 34969771 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg BMS-986278
Number of subjects: 360
Study 34969771 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg BMS-986278
Number of subjects: 360
Study 34969771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 33845761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 µg/kg/h)
Number of subjects: 139
Study 33845761 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 139
Study 32893313 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA (Neurally Adjusted Ventilatory Assist)
Number of subjects: 306
Study 32893313 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung-protective mechanical ventilation (MV)
Number of subjects: 306
Study 32893313 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 306
Study 32893313 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 306
Study 34981180 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day for 5 weeks)
Number of subjects: 99
Study 34981180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 32007328 — intervention group
Group type: EXPERIMENTAL
Intervention: Calling
Number of subjects: 547
Study 32007328 — intervention group
Group type: EXPERIMENTAL
Intervention: Job satisfaction
Number of subjects: 547
Study 32007328 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration, workload, relationships with colleagues, work itself, remuneration and benefits
Number of subjects: 547
Study 33829803 — intervention group
Group type: EXPERIMENTAL
Intervention: FORNET (Narrative Exposure Therapy for Forensic Offender Rehabilitation)
Number of subjects: 0
Study 33158948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise (LV-HIIE)
Number of subjects: 23
Study 33158948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous moderate-intensity aerobic exercise (CME)
Number of subjects: 23
Study 33158948 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 23
Study 33158948 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance index (IRI)
Number of subjects: 23
Study 33158948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipids
Number of subjects: 23
Study 32371448 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct electrical stimulation (DES)
Number of subjects: 75
Study 34730461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried egg white protein supplementation (20 g protein daily)
Number of subjects: 29
Study 34730461 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric maltodextrin supplement
Number of subjects: 29
Study 34723741 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief preexamination mindfulness intervention
Number of subjects: 49
Study 34723741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 33131393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical care for subacromial pain syndrome
Number of subjects: 98
Study 35240010 — intervention group
Group type: EXPERIMENTAL
Intervention: CT group
Number of subjects: 3561
Study 35240010 — intervention group
Group type: COMPARATOR
Intervention: ICA group
Number of subjects: 3561
Study 32166337 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature
Number of subjects: 145
Study 32166337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical signature
Number of subjects: 145
Study 32166337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined signature
Number of subjects: 145
Study 33407805 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-led e-cigarette prevention program
Number of subjects: 0
Study 33407805 — intervention group
Group type: EXPERIMENTAL
Intervention: Elected peer-leader led e-cigarette prevention program
Number of subjects: 0
Study 33407805 — intervention group
Group type: EXPERIMENTAL
Intervention: Random peer-leader led e-cigarette prevention program
Number of subjects: 0
Study 32102946 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2333
Study 32102946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2333
Study 35356054 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minutes of daily morning bright white light (BWL)
Number of subjects: 39
Study 35356054 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL)
Number of subjects: 39
Study 35353757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease (congestive heart failure or hypertension)
Number of subjects: 47
Study 32556699 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) with standard intraabdominal pressure (IAP) 20 mmHg
Number of subjects: 62
Study 32556699 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) with low intraabdominal pressure (IAP) 12 mmHg
Number of subjects: 62
Study 32556699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade (NMB) with low intraabdominal pressure (IAP) 12 mmHg
Number of subjects: 62
Study 32556699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade (NMB) with standard intraabdominal pressure (IAP) 20 mmHg
Number of subjects: 62
Study 32854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal drink
Number of subjects: 55
Study 32854375 — intervention group
Group type: COMPARATOR
Intervention: Least optimal drink
Number of subjects: 55
Study 32854375 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 55
Study 34713539 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily (SDD40)
Number of subjects: 235
Study 34713539 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 235
Study 34970565 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted System (CAD)
Number of subjects: 6
Study 34970565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CAD)
Number of subjects: 6
Study 33885773 — intervention group
Group type: EXPERIMENTAL
Intervention: Default dispense quantity of 10 tablets
Number of subjects: 21331
Study 33885773 — intervention group
Group type: COMPARATOR
Intervention: No change in EHR
Number of subjects: 21331
Study 34325109 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m2 followed by trabectedin 1.1 mg/m2 as a 3‐h infusion on day 1 and pegfilgrastim on day 2, every 3 weeks, up to six cycles
Number of subjects: 108
Study 32428430 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) implementation
Number of subjects: 248
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin T (cTnT-hs)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth differentiation factor-15 (GDF-15)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 (FGF-23)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase receptor (uPAR)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: Trefoil factor 3 (TFF3)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor receptor 1 (TNFR1)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2)
Number of subjects: 517
Study 34358298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathepsin L1 (CTSL1)
Number of subjects: 517
Study 32956959 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience and interpersonal relationships
Number of subjects: 450
Study 32956959 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 450
Study 32956959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal relationships
Number of subjects: 450
Study 32612088 — intervention group
Group type: EXPERIMENTAL
Intervention: OPLFE
Number of subjects: 25
Study 32612088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed plant extract with OPLFE
Number of subjects: 25
Study 32612088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 34674896 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser therapy (Ga-As super pulsed laser therapy)
Number of subjects: 36
Study 34674896 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy (inactive laser)
Number of subjects: 36
Study 34064427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block (FICB) with 0.375% ropivacaine, nonopioid analgesics (paracetamol, metamizole, pregabalin), and oxycodone as rescue analgesia
Number of subjects: 109
Study 34064427 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous analgesia with FICB
Number of subjects: 109
Study 35884677 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 24
Study 35884677 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography bridge (EMGB)
Number of subjects: 24
Study 34393206 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 14
Study 34393206 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.25%
Number of subjects: 14
Study 34393206 — intervention group
Group type: COMPARATOR
Intervention: No medications
Number of subjects: 14
Study 36272295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin ear drops
Number of subjects: 70
Study 36272295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline gauze (VG)
Number of subjects: 70
Study 36272295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry gelfoam alone
Number of subjects: 70
Study 33560754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-loading exercises (weight-bearing and resistance training) for 12 months
Number of subjects: 72
Study 33560754 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy strategies
Number of subjects: 72
Study 33560754 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to exercise
Number of subjects: 72
Study 36619342 — intervention group
Group type: EXPERIMENTAL
Intervention: Big patch (30,000 IU cholecalciferol)
Number of subjects: 30
Study 36619342 — intervention group
Group type: EXPERIMENTAL
Intervention: Small patch (30,000 IU cholecalciferol)
Number of subjects: 30
Study 36619342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patches (30,000 IU cholecalciferol)
Number of subjects: 30
Study 36409638 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous void (SV)
Number of subjects: 109
Study 36409638 — intervention group
Group type: COMPARATOR
Intervention: Retrograde fill (RF)
Number of subjects: 109
Study 32621248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention targeting physiotherapists
Number of subjects: 174
Study 32621248 — intervention group
Group type: COMPARATOR
Intervention: Intervention targeting surgeons
Number of subjects: 174
Study 32680778 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation using bone marrow-derived mesenchymal stem cells
Number of subjects: 3
Study 32680778 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage procedure with accelerated rehabilitation
Number of subjects: 3
Study 32424502 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 326
Study 35049477 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 4 Health (G4H)
Number of subjects: 174
Study 35049477 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 174
Study 33285673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture (TEA) combined with acupuncture (AT)
Number of subjects: 38
Study 33285673 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (AT)
Number of subjects: 38
Study 36272766 — intervention group
Group type: EXPERIMENTAL
Intervention: Montage bone putty and wire cerclage
Number of subjects: 60
Study 36272766 — intervention group
Group type: COMPARATOR
Intervention: Wire cerclage alone
Number of subjects: 60
Study 34635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological contamination
Number of subjects: 642
Study 34635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical contamination
Number of subjects: 642
Study 34635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure environments
Number of subjects: 642
Study 34635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard signs/icons
Number of subjects: 642
Study 34635374 — intervention group
Group type: COMPARATOR
Intervention: Neutral scenes
Number of subjects: 642
Study 34635374 — intervention group
Group type: COMPARATOR
Intervention: Neutral icons
Number of subjects: 642
Study 32043347 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIEFAST
Number of subjects: 2